“Diabetes drug might hike heart risk” (SN: 6/23/07, p. 397) reports 86 heart attacks among 15,560 rosiglitazone (Avandia) users, versus 72 others in a control group of 12,283. A study coauthor then says that “after statistical adjustment, that yields a 43 percent higher risk of heart attacks among rosiglitazone users.”
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.